NCT06042387 Genome Analysis Across Populations in Inflammatory Bowel Disease
| NCT ID | NCT06042387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mount Sinai Hospital, Canada |
| Condition | Ulcerative Colitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-05-01 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2022-05-01 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
Eligibility Criteria
Inclusion Criteria: * Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined) * Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) * Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss * Any age Exclusion Criteria: \- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Contact & Investigator
Mark Silverberg, MD PhD
PRINCIPAL INVESTIGATOR
Sinai Health System
Frequently Asked Questions
Who can join the NCT06042387 clinical trial?
This trial is open to participants of all sexes, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06042387 currently recruiting?
Yes, NCT06042387 is actively recruiting participants. Contact the research team at joanne.stempak@sinaihealth.ca for enrollment information.
Where is the NCT06042387 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06042387 clinical trial?
NCT06042387 is sponsored by Mount Sinai Hospital, Canada. The principal investigator is Mark Silverberg, MD PhD at Sinai Health System. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.